Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 5/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.58 |
| ▸ | MAPT | P10636 | 4/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.58 |
| ▸ | GAA | P10253 | 2/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | HPGD | P15428 | 1/20 | 0.58 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.58 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.58 |
| ▸ | POLB | P06746 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 4/20 | 0.47 |
| ▸ | RAB9A | P51151 | 4/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.43 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.43 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4921577 | 1.00 | MEN1 (0.58) | MEN1KMT2AKDM4EMAPTSMN1; SMN2 | |
| SCHEMBL12230335 | 0.82 | KDM4E (0.64) | MEN1KMT2AKDM4EMAPTSMN1; SMN2 | |
| SCHEMBL4913013 | 0.80 | RAB9A (0.56) | MEN1KMT2AKDM4EMAPTSMN1; SMN2 | |
| SCHEMBL4913015 | 0.80 | RAB9A (0.56) | MEN1KMT2AKDM4EMAPTSMN1; SMN2 | |
| SCHEMBL12204615 | 0.80 | MEN1 (0.62) | MEN1KMT2AKDM4EMAPTSMN1; SMN2 | |
| SCHEMBL15934060 | 0.74 | KMT2A (0.70) | MEN1KMT2AKDM4EMAPTSMN1; SMN2 | |
| SCHEMBL10458447 | 0.72 | KDM4E (0.72) | MEN1KMT2AKDM4EMAPTSMN1; SMN2 | |
| SCHEMBL19435724 | 0.71 | HCAR2 (0.53) | MEN1KMT2AKDM4EMAPTSMN1; SMN2 | |
| SCHEMBL19435723 | 0.71 | HCAR2 (0.53) | MEN1KMT2AKDM4EMAPTSMN1; SMN2 | |
| SCHEMBL19435727 | 0.71 | HCAR2 (0.53) | MEN1KMT2AKDM4EMAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120214808-A1 | Aryl Urea Derivatives for Treating Obesity | PROSIDION LIMITED (GB) | 2012-08-23 | — | — | US | disclosed |
| US-20080261952-A1 | Aryl Urea Derivatives for Treating Obesity | PROSIDION LTD. (GB) | 2008-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080261952-A1 | Aryl Urea Derivatives for Treating Obesity | CNR1, GPR119, UTS2R | MEN1 4843/4885KMT2A 1905/4885KDM4E 1316/4885 |
| US-20120214808-A1 | Aryl Urea Derivatives for Treating Obesity | CNR1, GPR119, UTS2R | MEN1 4843/4885KMT2A 1905/4885KDM4E 1316/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.